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Abstract
Introduction: The goal of the study was an evaluation of serum vitamin D concentrations in healthy young women. 
Material and methods: A total of 106 healthy women, aged 20–30 years, were included in the study. Monthly evaluation — for three 
months — of the effects of calcium (500 mg) and vitamin D (1500 IU) administration in women with baseline values of vitamin D 
< 20 ng/mL (Group 1) plus the effects of an 800 IU/d dose in women with the baseline value of D > 20 ng/mL (Group 2). Additionally, 
calcium and PTH concentrations were assessed at the study onset and after a three-month supplementation. Only 67 women adhered to 
the prescribed therapeutic regime during the three months of observation.
Results: The mean vitamin D concentration in the entire study group was 16.56 ng/mL, being 12.6 ng/mL in Group 1 and 25.22 ng/mL 
in Group 2. In the course of vitamin D administration, its concentration increased statistically significantly, both in the entire group and 
in the subgroups, at all time points compared with the study onset. Moreover, its concentration in the whole population and in Group 
1 was significantly higher in each of the time points not only in relation to the baseline, but also in comparison with the results of the 
previous measurements (after 1 and 2 months of supplementation). In Group 2, vitamin D levels also increased systematically throughout 
the whole study period, and after 3 months its concentration was significantly higher than after 1 and 2 months. Although there were 
no differences in calcium concentration after those three months, a statistically significant drop of PTH (p < 0.05) was recorded in the 
entire population and in Group 1.
Conclusions: A moderate deficiency of vitamin D was observed in the studied population of young women. A supplementation with 
calcium plus vitamin D brought about an increase of vitamin D concentration as early as in the first month of administration. The optimal 
concentration of > 30 ng/mL was achieved in Group 1 after three months of vitamin D administration in 1500 IU/d dose. 
(Endokrynol Pol 2017; 68 (5): 533–540)
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Streszczenie
Wstęp: Celem badania była ocena stężeń witaminy D w surowicy u młodych kobiet.
Materiał i metody: Do badania zostało włączonych 106 zdrowych kobiet w wieku 20–30 lat. Uczestniczki badania z początkowym stężeniem 
witaminy D < 20 ng/ml (grupa 1) otrzymywały 500 mg wapnia oraz 1500 j.m. witaminy D na dobę, a kobiety z wyjściowym stężeniem 
witaminy D > 20 ng/ml (grupa 2) 500 mg wapnia oraz 800 j.m. witaminy D dziennie. Stężenie witaminy D badano co miesiąc. Ponadto 
u wszystkich pacjentek na początku badania i po 3 miesiącach suplementacji oceniano stężenia wapnia i PTH w surowicy. Tylko 67 kobiet 
przyjmowało leki zgodnie z zaleceniami.
Wyniki: Średnie stężenie witaminy D w całej populacji wyniosło 16,56 ng/ml oraz odpowiednio 12,6 ng/ml w Grupie 1 i 25,22 ng/ml 
w Grupie 2 (≥ 20 ng/ml). W wyniku zastosowanej podaży witaminy D odnotowano istotny statystycznie wzrost jej stężenia w całej 
populacji oraz w obu grupach, we wszystkich badanych punktach czasowych względem poziomu podstawowego. Ponadto stęże-
nie witaminy D w całej populacji oraz w Grupie 1 było znamiennie wyższe w każdym z badanych punktów czasowych nie tylko 
względem poziomu początkowego, ale również w stosunku do wyników poprzednich pomiarów (po 1 i 2 miesiącach suplementacji). 
W Grupie 2 stężenie witaminy D również wzrastało systematycznie w trakcie całego okresu obserwacji i po 3 miesiącach było istotnie 
wyższe w porównaniu z wartościami po 1 i 2 miesiącach. 
Mimo że nie było istotnych statystycznie różnic w stężeniu wapnia po 3 miesiącach, stwierdzono znamienny spadek PTH 
(p < 0,05) w całej populacji oraz w Grupie 1.
Wnioski: W badanej populacji młodych kobiet stwierdzono niedobór witaminy D. Suplementacja wapniem i witaminą D spowodowała 
znaczący wzrost stężenia witaminy D w surowicy już po pierwszym miesiącu leczenia. W Grupie 1 po 3. miesiącach podaży 1500 j.m. 
witaminy D na dobę uzyskano dolną wartość przedziału optymalnego stężenia tej witaminy w surowicy.  
(Endokrynol Pol 2017; 68 (5): 533–540)
Słowa kluczowe: witamina D, suplementacja, młode kobiety, wiek 20–30 lat
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Introduction
Calcium is a mineral component that is very important 
not only for the skeleton structure but also as a nutri-
ent, required for nerve conduction, muscle contraction, 
hormone and enzyme secretion, and blood clotting. An 
adequate calcium intake is essential for normal growth 
and development of the skeleton and teeth and also for 
adequate bone mineralisation. Optimised bone mass 
accretion in youth and adolescence is critical to attain-
ing peak bone mass in adulthood [1]. In adulthood, 
low calcium intake is associated with an increased risk 
for osteoporosis [2], bone fractures, and falls [3, 4]. The 
Institute of Medicine supports the key combined role 
of calcium and vitamin D in the maintenance of skeletal 
health, recommending a daily intake of 1.2 g of calcium 
and 800 IU of vitamin D for women in their prime [5].
Vitamin D helps calcium absorption and its role in 
bone health has been well characterised [6]. Vitamin D 
and calcium are necessary for proper modelling and 
remodelling of bones and the optimal bone mass de-
pends on their appropriate supplementation. Vitamin 
D is also responsible for modulation of cell growth, 
neuromuscular and immune function, and reduction 
of inflammation [7]. It has been shown that high-dose 
vitamin D3 significantly reduced CD4+ T-cell activation 
compared to low-dose vitamin D3, providing human 
evidence that vitamin D can influence cell-mediated 
immunity [8].
Apart from maintaining adequate serum calcium 
and phosphate concentrations, there is some evidence 
that vitamin D may help prevent colon, prostate, and 
breast cancers [7]. Vitamin D deficiency may contrib-
ute to certain chronic diseases [9]. It may also play an 
important role in the prevention and treatment of 
diabetes [10, 11], cardiovascular disease [12], chronic 
heart failure and autoimmune diseases (e.g. multiple 
sclerosis, chronic thyroiditis, ulcerative colitis) [13], 
mental illnesses, such as depression [14], schizophrenia 
[15, 16], neurodevelopmental disorders, and intellectual 
disabilities [17]. 
In humans, the major volumes of circulating vitamin 
D are synthesized from cholesterol, following exposure 
to sunlight ultraviolet B, whereas a smaller amount is 
derived from diet and dietary supplements. Diet con-
tributes only between 10% and 20% to 25(OH)D levels, 
but becomes more important when sunshine exposure 
is low [18]. Calcium in the diet contributes to about 50% 
of the recommended intake [5].
Vitamin D deficiency and insufficiency are re-
spectively defined as 25(OH)D levels < 20 ng/mL 
(50 nmol/L) and 25(OH)D between 20 and 29 ng/mL 
(50 nmol/L and 75 nmol/L), although different defini-
tions exist [19]. In Europe, the mean serum 25(OH)D 
levels, reported in population-based studies, vary from 
18 ng/mL (29 nmol/L) in Italy to 30 ng/mL (75 nmol/L) 
in Norway [20]. It has been observed that more than 
40% of U.S. and European men and women, and more 
than 50% of postmenopausal women, are affected by 
vitamin D deficiency [7, 21], including Poland, where 
it is found in approximately 90% of the general popu-
lation [22–24]. In some populations, the deficit is ever 
stronger, e.g. 98.8% of Mongolian women, 18–44 years 
of age, demonstrate serum 25(OH)D < 20 ng/mL 
(50 nmol/L) [25]. There are some factors that can influ-
ence the deficiency of vitamin D, e.g. in the Swiss adult 
population, the prevalence of vitamin D insufficiency or 
deficiency is high and varies by season, BMI category, 
and speaking region. The association of speaking re-
gions with vitamin D status is independent of major 
potential confounders [21]. 
Gahche et al. have shown that vitamin D supple-
ments have increased over time in adult populations, 
while their consumption by children and adolescents 
appears to be stable [26]. The daily contribution of sup-
plemental calcium in the United States (2005–2006) for 
women at the age of 19–30 years was 283 ± 18.7 mg/dL 
and the daily intake of vitamin D was 7.5 ± 0.7 ug. 
Calcium intake from diet, demonstrated by women at 
the age of 19–30 years, was 945 ± 29.8 mg/d and vitamin 
D intake was 5.8 ± 0.3 ug/d [27]. 
The goal of the study was an evaluation of serum 
vitamin D concentration in healthy women, aged 20–30 
years, and to update the prevalence of vitamin D de-
ficiency and insufficiency, defined as vitamin D Total 
(25(OH)D) less or more than 20 ng/mL. Additionally, 
in one-month evaluation — for three months — the 
effects of calcium (500 mg) and vitamin D (800 IU or 
1500 IU) supplementation were evaluated.
Material and methods
A total number of 106 healthy females, aged 20–30 years, 
were enrolled into the study. The exclusion criteria 
included:
1. Chronic administration of bone metabolism improv-
ing agents: bisphosphonates, strontium ranelate, so-
dium fluoride, denosumab, oestrogens or hormonal 
replacement therapy, selective oestrogen receptor 
modulators, glucocorticosteroids, anti-epileptic 
drugs, aromatase inhibitors, GnRH analogues, and 
chemotherapy. 
2. Endocrine disorders, significantly affecting bone 
resorption processes, such as: hyperparathyroidism, 
active hyperthyroidism, hyperprolactinaemia, and 
hypogonadism.
3. Chronic renal failure (glomerular filtration rate 
< 35 mL/min [25].
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4. Malabsorption.
5. Diagnosed cancer, malignant tumour, or process. 
6. Chronic systemic disease that could have signifi-
cantly affected bone metabolism.
7. Refusal to submit written consent to participate in 
the study.
The women were assigned to two groups, depend-
ing on baseline serum level of vitamin D. Group 1 
was composed of women with baseline vitamin D 
concentrations below 20 ng/mL and the rest of the 
study population formed Group 2. All the participants 
received daily oral supplementation of calcium (cal-
cium carbonate) in a dose of 1250 mg and vitamin D3 
in a dose of 1500 IU (Group 1) or 800 IU (Group 2) for 
three months. Calcium and vitamin D3 supplements 
were provided free of charge by their manufacturer 
(Axellus LLC). The adherence to therapy was assessed 
on the basis of patient declarations and returned empty 
drug packaging units. In cases of non-compliance 
to visit schedules, the patients were contacted by 
phone. 
The women who were qualified to the study paid 
visits every month in order to replenish their sup-
plement stock, for evaluation of compliance with 
prescribed supplement administration schedules and 
regimes and for planned examinations. Blood samples 
were collected from fasting patients at the inclusion 
visit and after 1, 2, and 3 months to assay total vitamin 
D, total calcium, phosphates, and alkaline phosphatase 
concentrations and after three months to assay para-
thormone (PTH) level. In order to exclude thyroid dys-
function, an additional blood sample was collected for 
baseline TSH assay. 
The women’ height and weight were measured 
and BMIs were calculated twice (at enrolment and 
after three months) in all the patients. All the enrolled 
patients remained under care of the Outpatient 
Clinic of Endocrinology throughout the whole study 
period. 
Only 67 women adhered to therapy during the 
three months of observation and completed the study. 
Laboratory tests
Biochemical assays were carried out by means of the 
following methods and sets:
1. Serum alkaline phosphatase concentrations, as 
well as total serum calcium and phosphate levels, 
were assessed using a colorimetric method with an 
Olympus analyser (Olympus Life and Material Sci-
ences, O’Callaghan’s Mills, Ireland) and Beckman 
Coulter (Brea, California) kits, according to the 
manufacturer’s instructions.
2. Serum total vitamin D (25-hydroxyvitamin D2 and 
25-hydroxyvitamin D3), PTH, and TSH concentrations 
were evaluated by the electrochemiluminescence 
method with a Cobas e411 analyser (Roche Diag-
nostics, Penzberg, Germany) and Roche Diagnostics 
kits in compliance with the manufacturer’s recom-
mendations. Reference values for total vitamin D 
levels were 30 to 70 ng/mL and for PTH 15 to 
65 pg/mL. 
The serum, used to assay total vitamin D, TSH, and 
PTH concentrations, was frozen immediately after cen-
trifugation of collected blood and stored at –70°C until 
use. The other laboratory tests, i.e. calcium, phosphate, 
and alkaline phosphatase concentrations in serum, 
were measured immediately after sampling. 
Statistical analysis
The study data are presented as means, means ± SD, 
and means ± SEM. For all statistical analyses, the level 
of significance (p value) was determined at 0.05. Data 
distribution normality was checked in each group, using 
the Shapiro-Wilk's test. 
In cases where there was no reason to reject the 
hypothesis that the distribution is normal, ANOVA 
with repeated measures was used. However, in cases 
of non-normal distribution, we used the Friedman test 
(or the Wilcoxon test for comparing two points). The 
Newman-Keuls test was used to compare significant 
differences between time points.
The Spearman’s rank correlation coefficient test was 
employed to evaluate correlations between assessed 
parameters.
In order to compare changes in vitamin D levels in 
relation to the categorised groups according to their 
baseline levels and their changes in time periods, two-
way repeated measure analysis of variance (ANOVA) 
was applied. In case of categorised measurements, the 
variables were independent. During ANOVA proce-
dures, not only simple effects were verified (e.g. the 
dependence between variable increase or decrease in 
terms of individual effect), but also interactions of ef-
fects were examined.
Results
In our study, the mean concentration of total vitamin 
D in the whole group was 16.56 ng/mL. During each 
month, we observed increased concentrations of this 
vitamin: the highest above 30 ng/mL after three months 
(Tab. I).
Vitamin D concentration changes for all the exam-
ined women at three time points of supplementation 
were statistically significant. We also observed significant 
differences between vitamin D levels in the second and 
third month, in comparison to its concentration in the 
first and second month of supplementation (Fig. 1).
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Statistically significant changes in PTH were ob-
served between baseline and after 3 months of sup-
plementation (Tab. II and Fig. 2).
Table I. Vitamin D concentrations in the whole population at 4 time points: 0 — at baseline; 1 — after 1 month; 2 — after 
2 months; 3 — after 3 months of calcium and vitamin D supplementation
Tabela I. Stężenia witaminy D w całej populacji w 4 punktach czasowych: 0 — na początku badania; 1 — po miesiącu; 2 — po 
2 miesiącach; 3 — po 3 miesiącach suplementacji wapnia i witaminy D
N Mean 95% CI Median SD SE Statistics chi2 Friedman’s Level p
Vitamin D (0) 67 16.5563 14.7295 18.3830 16.5500 7.4893 0.9150 120.10 < 0.0001
Vitamin D (1) 67 26.6491 25.1593 28.1390 26.5300 6.1080 0.7462
Vitamin D (2) 67 29.0546 27.3083 30.8010 27.6500 7.1594 0.8747
Vitamin D (3) 58 32.1688 30.2726 34.0650 32.7600 7.2117 0.9469
Figure 1. Vitamin D concentration changes for the whole 
population at 3 time points of continued supplementation
Rycina 1. Zmiany stężenia witaminy D w całej populacji w 3 
punktach czasowych w trakcie stosowania ciągłej suplementacji
Table II. Correlations between some parameters at baseline 
and after 3 months of supplementation for all the examined 
groups
Tabela II. Korelacje między wartościami niektórych 
parametrów zmierzonymi na początku badania i po 
3 miesiącach suplementacji we wszystkich grupach badanych
N T Statistics Normalized 
Z statistics
 p value
PTH (0) & PTH (3) 58 288.000 4.393782 0.0000
ALP (0) & ALP (3) 58 750.000 0.391540 0.6954
Ca (0) & Ca (3) 67 1055.000 0.322598 0.7470
P (0) & P (3) 58 657.000 1.536856 0.1243
BMI (0) & BMI (3) 64 434.00 0.470923 0.6377
Figure 2. Changes in PTH concentration at baseline and after 
3 months of supplementation
Rycina 2. Zmiany stężenia PTH po 3 miesiącach suplementacji 
w porównaniu z wartościami początkowymi
In whole group, no correlation was observed be-
tween changes in PTH and vitamin D concentrations 
and between changes in BMI and vitamin D (data not 
shown).
In Group 1 (patients with baseline total vitamin D 
level < 20 ng/mL), which was supplemented with daily 
dose of 500 mg of calcium and 1500 IU of vitamin D, we 
observed a statistically significant increase in vitamin D 
throughout the whole study period (Tab. III). Significant 
differences were noticed between vitamin D levels in 
the second and third month, in comparison to its con-
centrations in the first month of supplementation (see 
Fig. 3). The highest rise of vitamin D was seen after the 
first month of its supplementation.
In Group 2 (patients with baseline total vitamin D 
level > 20 ng/mL), which was supplemented with daily 
dose of 500 mg of calcium and 800 IU of vitamin D, we 
also noticed a statistically significant increase of vitamin 
D throughout the whole study period (see Table IV).
The increase of vitamin D during three months was 
not as great as in the group of women with deficit and 
deficiency of vitamin D (< 20 ng/mL). In that group, 
significant differences were noticed among vitamin D 
levels in the third month in comparison to its concentra-
tion in the first and the second month of supplementa-
tion (Fig. 4).
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Table III. Vitamin D concentrations in Group 1 at 4 time points: 0 — at baseline; 1 — after 1 month; 2 — after 2 months; 
3 — after 3 months of calcium and vitamin D supplementation
Tabela III. Stężenia witaminy D w grupie 1 w 4 punktach czasowych: 0 — na początku badania; 1 — po miesiącu; 2 — po 
2 miesiącach; 3 — po 3 miesiącach suplementacji witaminy D
N Mean 95% CI Median SD SE chi2 Friedman's 
statistics
p value
Vitamin D (1) 46 12.6020 11.1698 14.0342 12.5600 4.8228 0.7111 80.07 < 0.0001
Vitamin D (2) 46 24.9750 23.4069 26.5431 24.8900 5.2805 0.7786
Vitamin D (3) 46 27.8354 25.7302 29.9406 27.3550 7.0891 1.0452
Vitamin D (4) 36 29.4197 27.3702 31.4692 30.5200 6.0573 1.0095
Table IV. Vitamin D concentrations in Group 2 at 4 time points: 0 — at baseline; 1 — after 1 month; 2 — after 2 months; 
3 — after 3 months of calcium and vitamin D
Tabela IV. Stężenia witaminy D w grupie 2 w 4 punktach czasowych: 0 – na początku badania; 1 — po miesiącu; 2 — po 
2 miesiącach; 3 — po 3 miesiącach suplementacji wapnia i witaminy D
N Mean 95% CI Median SD SE chi2 Friedman's statistics p value
Vitamin D (1) 21 25.2171 23.2826 27.1517 24.9500 4.2499 0.9274 35.27 < 0.0001
Vitamin D (2) 21 30.3162 27.4441 33.1882 28.1400 6.3095 1.3768
Vitamin D (3) 21 31.7252 28.6660 34.7845 31.5000 6.7207 1.4666
Vitamin D (4) 19 36.9189 33.8510 39.9869 36.9500 6.3652 1.4603
We also compared vitamin D level changes in rela-
tion to categorised groups, according to their baseline 
levels (0–10 ng/mL; 10–20 ng/mL; > 20 ng/mL) and their 
changes over time periods. The increase of vitamin D 
concentrations in the group 0–10 ng/mL was signifi-
cantly higher than that in the other two groups (10–20 
and > 20 ng/mL) in all the examined time periods. 
The rise of vitamin D levels in group 10–20 ng/mL in 
comparison to group > 20 ng/mL was insignificant dur-
ing any of the time periods (Tab. V and Fig. 5). 
Discussion
Vitamin D and calcium deficiencies are preventable glob-
al public health problems in infants, children, and ado-
lescents. According to international rickets prevention 
Figure 3. Changes in total vitamin D concentrations at baseline 
and after 1, 2, and 3 months of supplementation in Group 1
Rycina 3. Zmiany stężenia całkowitej witaminy D w grupie 1 
po 1, 2 i 3 miesiącach suplementacji w porównaniu z wartościami 
początkowymi
Figure 4. Changes in total vitamin D concentration at baseline 
and after 1, 2, and 3 months of supplementation in Group 2
Rycina 4. Zmiany stężenia całkowitej witaminy D w grupie 2 
po 1, 2 i 3 miesiącach suplementacji w porównaniu z wartościami 
początkowymi
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programs, implementation, including supplementa-
tion and food fortification, is an urgently required 
measure [28, 29]. 
The role of adequate calcium and vitamin D intake 
benefits in health and the prevention of several chronic 
diseases has been the main focus for many scientists in 
the past few decades. Most of the observations have 
shown a positive influence of supplementation [13, 17]. 
Some facts, which indicate that not only osteoporosis, 
but also obesity, cancer, diabetes, hypertension, and oth-
ers may be linked to inadequate calcium and vitamin D 
metabolism [30–35], suggests an extraordinary potential 
in these two agents [36]. However, some authors raise 
the question of whether the role of calcium and vitamin 
D is overweighed [37].
The Institute of Medicine supports the key role of 
calcium and vitamin D in the maintenance of skeletal 
health and recommended a daily intake of 1.2 g of 
calcium and 800 IU of vitamin D for women in older 
age [5]. In Poland, 90% of people have insufficiency of 
vitamin D [23, 24, 38]. 
The goal of our study was to examine vitamin 
D concentrations in a population of young, healthy 
women and to evaluate the optimal dose of vitamin D 
supplementation. Daily supplementation of calcium in 
the United States for women aged 19–30 years is 283 ± 
18.7 mg/dL and daily intake of vitamin D 7.5 ± 0.7 ug 
(300 ± 28 IU) [27]. In our study, the women, aged 
20–30 years, were divided into two groups depending 
on total vitamin D concentration at baseline. Serum 
total vitamin D consists of 25-hydroxyvitamin D2 and 
25-hydroxyvitamin D3. In Poland, there is no vitamin 
D2 in tablets. Our source of this vitamin is thus limited 
to diet. In Group 1, which received supplementation of 
1250 mg of calcium carbonicum and 1500 IU vitamin D 
for three months, the concentration of total vitamin D 
increased by about 16 ng/mL from 12.60 ± 0.71 ng/mL 
to 29.42 ± 1.01 ng/mL. Similarly, in Group 2, which 
received 1250 mg of calcium carbonicum and a supple-
mentation of 800 IU vitamin D for three months, the 
concentration of vitamin D total increased by about 
12 ng/mL from 25.22 ± 0.93 ng/mL to 36.92 ± 1.46 ng/mL. 
The study was started in January and finished in May. 
It is comparable with other observations. In a study of 
112 white women, aged 19 to 35 years, randomly as-
signed to placebo or 800 IU/d vitamin D3 for one year, 
Table V. Vitamin D concentration changes between: baseline and after 1 month (1), after 2 months (2), and after 3 month (3) 
in 3 subgroups of women with concentration of vitamin D at the baseline 0–10 ng/mL; 10–20 ng/mL; and > 20 ng/mL
Tabela V. Zmiany stężenia witaminy D w stosunku do wartości wyjściowych po miesiącu (1), 2 miesiącach (2) i 3 miesiącach 
(3) w 3 podgrupach kobiet z początkowym stężeniem witaminy D wynoszącym 0–10 ng/ml, 10–20 ng/ml i > 20 ng/ml
Vitamin D ng/
ml (0)
Changes in 
concentrations
N Mean SD SE
0–10 Changes vit. D (1) 15 2.6404 1.6293 0.4207
Changes vit. D (2) 15 3.1049 2.1413 0.5529
Changes vit. D (3) 15 3.5773 2.6802 0.6920
10–20 Changes vit. D (1) 31 0.7175 0.2391 0.0429
Changes vit. D (2) 31 0.9431 0.4719 0.0848
Changes vit. D (3) 25 1.1091 0.4213 0.0843
> 20 Changes vit. D (1) 21 0.2185 0.2569 0.0561
Changes vit. D (2) 21 0.2778 0.3079 0.0672
Changes vit. D (3) 18 0.4358 0.2345 0.0553
Figure 5. Statistical analysis of changes in vitamin D levels in 
relation to the categorised groups, according to their baseline levels 
(0–10 ng/mL; 10–20 ng/mL; > 20 ng/mL) and their changes over 
time periods. Bars represent 95% Confidence Intervals
Rycina 5. Analiza statystyczna zmian stężenia witaminy D w 
odniesieniu do podziału na grupy w zależności od wyjściowego 
stężenia tej witaminy (0–10 ng/ml; 10–20 ng/ml; > 20 ng/ml) 
oraz zmiany stężenia w różnych okresach. Słupki przedstawiają 
95% przedziały ufności
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the mean serum 25(OH)D levels increased by 14 ng/mL 
from 25 ng/mL to 39 ng/mL [39]. In a study, performed 
in winter in Antarctica, where exposure to ultraviolet 
B rays is zero, 55 men and women, aged 39 to 44 years, 
were given vitamin in D doses of 400, 1000, or 2000 IU/d. 
Mean serum 25(OH) D levels increased from baseline 
of 18 ng/mL to 23, 25, and 28 ng/mL, respectively [40]. 
In two placebo‐controlled studies of young men and 
women between 29 and 41 years old in Boston (MA, 
USA), 1000 IU/d of vitamin D2 or D3 increased serum 
25OHD from 18 to 28 ng/mL and from 20 to 28 ng/mL 
[41, 42]. Vitamin D3 supplementation with 1000 IU/d in 
children (aged 8–14 years) with mean baseline 25(OH)D 
concentration < 20 ng/mL effectively raised their mean 
25(OH)D concentration to ≥ 20 ng/mL but failed to reach 
30 ng/mL. In this paper vitamin D supplementation had 
no effect on PTH concentrations [43].
Other findings from our study include serum PTH 
drops after vitamin D intake. In the young women in 
Group 1, PTH decreased from 38.03 ± 1.69 to 28.85 
± 1.37 (p < 0.0001). In our observations, no correla-
tion was identified between PTH and total vitamin D. 
Other authors did find a significant inverse correlation 
between serum 25OHD and PTH [44, 45], but their 
examined populations were larger. There might also 
be another explanation for this. Shieh et al. observed 
that the percentage change in iPTH was significantly 
associated with change in free (but not total) vitamin 
D, without and with adjustment for supplementation 
regimen [46]. They suggested that vitamin D3 increased 
total (25-hydroxyvitamin D2 and 25-hydroxyvitamin 
D3) and free 25(OH)D levels to a greater extent than 
vitamin D2. Free 25(OH)D may be superior to total 
25(OH)D as a marker of vitamin D bioactivity.
We did not see any side effects during calcium and 
vitamin D supplementation. The women in our groups 
were young (20–30 years old). It was confirmed that 
the incidence of hypercalciuria and hypercalcaemia is 
lower in younger women than that reported for older 
women [47, 48].  
Our study authorises us to make a recommendation 
for the population of young women in Poland. A dose 
of vitamin 1500 IU/d increases total serum vitamin D 
concentration by 17 ng/mL, whereas 800 IU/d increases 
serum 25OHD by 12 ng/mL in young white women. 
Recently, the IOM suggested that RDA for people at 
the age group 19 to 50 years should be 600 IU/d [5]. In 
Poland, according to our recommendations, the dose of 
vitamin D should be higher [49], especially in case of its 
deficiency, which is often seen in younger populations 
who are still building peak bone mass.
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